/
IART
$18.13-$0.61 (-3.26%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$1.5B
78M shares
52-week range
$8.70 – $18.92
92% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.60%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-51.00
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.47B | $1.52B | $1.37B | $1.54B | $1.56B | $1.54B | $1.61B | $1.64B |
| Cost of revenue | $571.5M | $564.7M | $520.8M | $597.8M | $587.4M | $656.8M | $728.5M | $790.0M |
| Gross profit | $900.9M | $952.9M | $851.0M | $944.6M | $970.3M | $884.7M | $882.1M | $845.2M |
| Gross margin | 61.2% | 62.8% | 62.0% | 61.2% | 62.3% | 57.4% | 54.8% | 51.7% |
| R&D | $78.0M | $79.6M | $77.4M | $93.1M | $101.2M | $104.2M | $115.4M | $99.0M |
| Operating income | $111.0M | $93.8M | $151.4M | $197.2M | $238.9M | $111.5M | $28.4M | $68.3M |
| EBITDA | $241.0M | $223.5M | $267.9M | $366.3M | $384.6M | $256.0M | $193.3M | −$326.2M |
| Net income | $60.8M | $50.2M | $133.9M | $169.1M | $180.6M | $67.7M | −$6.9M | −$516.5M |
| Net margin | 4.1% | 3.3% | 9.8% | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| EPS (diluted) | 0.72 | 0.58 | 1.57 | 1.98 | 2.16 | 0.84 | -0.09 | -6.73 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.7B | $2.45 | $2.42–$2.46 | 6 |
| 2027 | $1.7B | $2.62 | $2.53–$2.69 | 6 |
| 2028 | $1.8B | $2.86 | $2.37–$3.35 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$23.07
Price
$18.13
Implied upside
+27%
Peer comparison
Integra LifeSciences Holdings
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
www.integralife.com- Employees
- 4,427
- IPO / List date
- Aug 16, 1995
- HQ
- PRINCETON, NJ
Held by traders on TradeandTell
No one on the platform currently holds IART.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2024-09-30 | 29,533 | $536.6K |
| Renaissance Technologiesas of 2025-12-31 | 14,760 | $183.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-01-04 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded IART yet.
